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Will savings from biosimilars offset
increased costs related to dose escalation?
A comparison of infliximab and golimumab
for rheumatoid arthritis
Jeffrey R. Curtis1* , Fenglong Xie1, Jonathan Kay2 and Joel D Kallich3
Abstract
Introduction: Biosimilar infliximab has the potential for appreciable cost savings compared to its reference biologic,
but dose escalation is common and increases costs. We compared frequency of dose escalation and associated
Medicare-approved amount so as to determine the break-even point at which infliximab dose escalation would
offset the cost savings of using a biosimilar, referent to alternatively using golimumab.
Methods: We studied Medicare enrollees with rheumatoid arthritis (RA) initiating infliximab or golimumab.
Frequency of dose escalation was summarized descriptively over 18 months, as were Medicare-approved amounts
for reimbursement. Analyses were repeated conditioning on high adherence (i.e., non-discontinuation, > 10-week
gap). Multivariable-adjusted logistic regression and mixed models evaluated factors associated with infliximab dose
escalation.
Results: A total of 5174 infliximab and 2843 golimumab initiators were observed. Dose escalation was rare for
golimumab (5%) but common for infliximab (49%), and was even more common (72%) for infliximab among
patients who persisted on treatment. Regardless of dose escalation, the adjusted least square mean dollar amounts
were appreciably higher for golimumab ($28,146) than for infliximab ($21,216) and greater among persistent
patients (cost difference $9269, favoring infliximab). Only when patients escalated infliximab to ≥ 8 mg/kg every 6
weeks was golimumab IV at break-even or less expensive. After controlling for multiple factors, physician ownership
of the infusion center was associated with greater likelihood of infliximab dose escalation (odds ratio = 1.25, 95% CI
1.09–1.44).
Conclusion: Despite frequent dose escalation with infliximab that often increase its dose by threefold or more, the
savings from the current price of its biosimilar substantially offsets the costs of an alternative infused TNFi biologic
for which no biosimilar is available.
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Introduction
In the United States (US), the Biologics Price Competi-
tion and Innovation (BPCI) Act of 2009 created an
abbreviated pathway for the Food and Drug Administra-
tion (FDA) to approve biological products that have
been demonstrated to be structurally and functionally
“highly similar” to an already approved biologic without
clinically meaningful differences [1, 2]. As of September
2019, 23 such “biosimilars” have been approved in the
US, offering the potential to provide meaningful cost
savings for treating chronic diseases such as rheumatoid
arthritis (RA) for which long-term use of costly biologics
is common [3]. Indeed, the annual global sales for TNF
inhibitors (TNFi) was $43.4 billion in 2017 [4]. Of the 23
FDA-approved biosimilars, 9 are TNF inhibitors (TNFi):
4 adalimumab biosimilars, 2 etanercept biosimilar, and 3
infliximab biosimilars. However, only 2 of the 3 inflixi-
mab biosimilars are currently marketed in the US;
because of patent-related issues, the adalimumab and
etanercept biosimilars are not yet available.
The context in which biosimilars compete with their
reference products, and its associated impact on cost, is
highly dependent on local and regional policies and
payers. For example, in the European Union, as of
September 2019, 55 of 61 biosimilars approved by the
European Medicines Agency were commercially avail-
able [5]. In some European Economic Area countries
such as Norway, hospital-administered medications are
purchased by a single payer using a competitive tender
system. By this process, the single payer can negotiate
aggressively for discounted acquisition costs, which has
realized savings of up to 70% for biosimilar infliximab
compared to its reference product [6]. Alternatively,
competition created by the introduction of a biosimilar
may result in savings by driving down the price of the
bio-originator. In late 2018, AbbVie won the Swedish
national tender for adalimumab by dropping its price for
the bio-originator by 80% [7]. Thus, in countries in
which there are single payer systems and “winner-take-
all” competitive bidding for drug acquisition, the prom-
ise of significant cost savings with the availability of
biosimilars is in fact being realized [8]. However, in the
US healthcare system, in which payers and their phar-
macy benefit managers may negotiate undisclosed
reductions in drug prices based upon discounts and
rebates from manufacturers, the availability of biosimilar
infliximab has resulted in only a 22% reduction of the
average selling price (ASP) of biosimilar infliximab com-
pared to that of its reference product [9, 10]. Medicare is
the largest single payer of biologic medications in the US,
yet the Medicare program has a much more limited ability
to negotiate price compared to its European counterparts,
making the magnitude of biosimilar discounting import-
ant from a policy and health economic perspective.
A unique aspect of some biologics used to treat RA is
the potential for on-label dose escalation. This might
take the form of an increase either in the dose adminis-
tered or in the dosing frequency, or both. Infliximab, a
TNFi indicated for the treatment of a number of inflam-
matory diseases, can be escalated in this way. Given past
findings of relatively frequent infliximab dose escalation,
we conducted an analysis of Medicare data to compare
the frequency of dose escalation and the total Medicare-
approved dollar amount for infliximab compared to
intravenous golimumab, the only other TNFi medication
administered by infusion and which has relatively similar
disease indications. The purpose of the analysis was to
test the hypothesis that dose escalation of infliximab
might offset the potential savings from using biosimilar
infliximab, contrasted with the use of an alternative
TNFi (golimumab) for which a biosimilar is neither
available nor expected in the near future.
Methods
Overview
We constructed a cohort of new infliximab and golimu-
mab IV users to evaluate descriptively the frequency of
dose escalation for each drug, persistence on treatment,
and associated Medicare-approved dollar amounts for
reimbursement. We further examined factors associated
with infliximab dose escalation to evaluate whether
provider-level variability was a factor that influenced
dose escalation, given that physician prescribing prac-
tices are potentially modifiable. Finally, we used the
results from these analyses to populate a hypothetical
cost model that evaluated the extent of infliximab dose
escalation which would be required to offset the dollar
savings derived from use of biosimilar infliximab, refer-
ent to an alternative strategy of instead using golimumab
IV, an infused TNFi for which no biosimilar is available.
Our analysis is thematically similar to an ongoing, phase
4 comparative pragmatic trial that is examining the fre-
quency of dose escalation, persistence on treatment, and
other outcomes associated with use of golimumab IV
versus infliximab in RA (clinicaltrials.gov NCT02728934;
https://clinicaltrials.gov/ct2/show/NCT02728934).
Cohort eligibility
Using the Centers for Medicare and Medicaid Services
(CMS) fee-for-service Medicare data from 2012 to 2016,
we assembled two cohorts of RA patients initiating
either infliximab or intravenous golimumab to compare
dose escalation, persistence on treatment, and amount
paid by the Medicare program. To be eligible for ana-
lysis, patients must have had a claim for reimbursement
for RA, identified using ICD9-CM diagnostic codes
(ICD9: 714.0, 714.2, 714.81; ICD10: M05.*, M06.*) from
rheumatologists. The date of first administration was
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defined as the index date for each patient, and the 12-
month period preceding the index date was defined as
“baseline.” All patients must have had their index date in
2013 or later, given that was the year of golimumab IV
licensure in the US for RA. Patients were required to be
new users of each of these therapies, with no claims for
reimbursement of these drugs, in both the baseline
period and all preceding available data (if more was
available). Additional covariates of interest (e.g., use of
methotrexate (MTX) and glucocorticoids (GC)) were ex-
amined during the 12-month baseline period. All pa-
tients were required to have Medicare part A, B, and D
coverage during the 12-month baseline period and for
the 78 weeks after the index date. Patients were permit-
ted to contribute (at most) one exposure episode to the
infliximab cohort and/or to the golimumab cohort, if
they met all criteria above.
Biologic exposure and definitions of dose escalation
Infliximab and golimumab for intravenous use (IV) were
identified using Healthcare Common Procedure Coding
System (HCPCS) codes (J1745 for bio-originator inflixi-
mab, Q5102 for biosimilar infliximab-dyyb, and J1602
for golimumab IV; codes Q5103 and Q5104 were not
used until April 1, 2018, and thus were not included in
these data), as well as using National Drug Codes
(NDCs) [11, 12]. NDCs for infliximab or golimumab IV
drug dispensation followed by the HCPCS code for its
administration within 7 days were consolidated into a
single claim. To treat RA, infliximab is typically adminis-
tered at an initial dose of 3 mg/kg and golimumab IV at
a fixed dose of 2 mg/kg. Because infliximab is dispensed
in 100 mg vials and golimumab IV in 50mg vials, each
dose administered was rounded up to the nearest 100
mg increment (for infliximab) or 50 mg increment (for
golimumab IV). RA patients who initiated therapy either
at an implausibly low starting dose (e.g., ≤ 100 mg inflixi-
mab or ≤ 50mg golimumab IV) or at an implausibly
high starting dose (≥ 1000 mg infliximab or ≥ 350 mg
golimumab IV) were excluded. Fewer than 1% of all
initiations were excluded for this reason.
A dose increase was defined as an increase of ≥ 100
mg (infliximab) or ≥ 50mg (golimumab IV) compared to
the initial dose. The maximum plausible dose of inflixi-
mab and golimumab IV allowable (after the starting
dose) was capped at 1500mg and 600mg, respectively.
Increase in frequency was defined by any pairwise inter-
val shorter than the usual 8-week dosing schedule com-
mon to both drugs, after the initial loading dose (0, 2,
and 6 weeks for infliximab, and 0 and 4 weeks for goli-
mumab IV). The pairwise intervals between infusions
were rounded up to the nearest week to be conservative.
For example, an interval of 50–62 days between infu-
sions would be considered compatible with an 8-week
dosing interval. Dose escalation was defined as either a
dose increase or an increase in dosing frequency. To de-
fine dose escalation conservatively, and because irregular
patient scheduling or other factors might lead to what
would incorrectly appear to be a dose increase, we re-
quired that dose increase or dosing interval shortening
occurs at two consecutive infusions in order to satisfy
the dose escalation criteria. A subgroup analysis was per-
formed on patients who remained on therapy (see defin-
ition below) to evaluate both the frequency of dosing
and the Medicare-approved dollar amounts associated
with each of the two infused TNFi among these patients.
A sensitivity analysis was also conducted that required
only a single dose increase or frequency shortening, ra-
ther than require an increase at two consecutive infu-
sions, as in the main analysis.
Outcomes of interest
The primary outcomes of interest were the frequency of
dose escalation and the amount paid by Medicare
through 78 weeks (day 546) following treatment initi-
ation. Non-persistence (i.e., treatment discontinuation)
was a secondary outcome, defined by either a ≥ 10-week
gap without the medication, or switching to another bio-
logic treatment for RA. A composite outcome of time to
either discontinuation or dose escalation was also exam-
ined. Medication “payments” were obtained directly
from the Medicare raw data as the Medicare-approved
dollar amount which is the full payment for covered
services for providers who accepts assignment, as listed
on each infusion claim. The Medicare-approved dollar
amount is the maximum amount approved by Medicare
for which a medical service, including infused medica-
tions, can be reimbursed. Medicare typically pays 80% of
this amount; the rest is collected from either the patient
as coinsurance or a supplemental insurance policy such
as Medigap.
Statistical analysis
Descriptive statistics were used to compare the inflixi-
mab and golimumab IV cohorts at baseline. Patient
covariates of interest included age, sex, race, disability as
the reason for Medicare eligibility (given that RA itself is
a common reason for qualifying for Medicare), dual eli-
gible beneficiaries (i.e., eligible for both Medicare and
Medicaid, a program for individuals and families with
low income and limited resources), comorbidities such
as chronic pulmonary disease, RA-related treatments
(e.g., methotrexate, NSAIDs) and other chronic medica-
tions, and measures of healthcare utilization including
number of physician visits and inpatient hospitalization.
Rheumatology providers were assigned uniquely to
each patient based on that office visit with an RA diag-
nosis code, which was most proximate to and prior to
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the date of infliximab or golimumab IV initiation. Phys-
ician ownership of the infusion center was assigned
based on whether the physician billed under his or her
own NPI or was part of a group that billed for infusions.
A Data Use Agreement governed use of all of the CMS
data, and the analysis was approved by the University of
Alabama at Birmingham Institutional Review Board. All
analyses were performed in SAS 9.4.
Cohort analysis evaluating persistence, Medicare-approved
amounts, and factors associated with infliximab dose
escalation
Kaplan-Meier curves were used to evaluate drug discon-
tinuation through week 78, and separately, a composite
outcome of discontinuation or dose escalation. Logistic
regression was used to generate a propensity score for
receipt of infliximab versus golimumab and to control
for differences in baseline factors. The propensity score
was then used to create inverse probability of treatment
weights (IPTW) and applied to a generalized linear
model procedure with a gamma distribution to calculate
adjusted least square means of infliximab and golimu-
mab IV users.
Among both bio-originator and biosimilar infliximab
users only, a separate logistic regression model was cre-
ated to evaluate the likelihood that patients were dose
escalated on infliximab (referent to not escalated) and to
evaluate baseline factors that might be associated with
dose escalation. Mixed models were used to account for
the clustered nature of the data (i.e., patients are treated
within rheumatology practices). A variety of covariates
were examined that were hypothesized to be associated
with the the likelihood that a physician might dose escal-
ate, including physician characteristics (e.g., ownership
of infusion center), and patient factors including age,
sex, race, disability, dual eligibility (commonly a proxy
for lower income), comorbidities, conventional synthetic
DMARDs, oral glucocorticoids, NSAIDs, opioids, anti-
depressants, and proxies for health-seeking behaviors
and screening including use of statins, anti-hypertensive
medications, lipid lowering medications, and breast can-
cer screening. Given the low frequency of dose escal-
ation for golimumab IV, no modeling was performed for
golimumab IV dose escalation.
Break-even analysis of infliximab dose escalation versus use
of golimumab IV
A hypothetical modeling scenario was run that com-
pared dose-escalated infliximab versus golimumab IV,
using the actual Medicare-approved amounts by Medi-
care in the first quarter of 2016, to evaluate the extent of
infliximab dose escalation that would be required to
offset the higher Medicare-approved amount for golimu-
mab. This modeling took into account a range of
potential discounts for biosimilar infliximab and assum-
ing one of several body weights (60, 70, 80, and 120 kg).
Uptake of biosimilar infliximab through December 2017
Finally, to examine more contemporary data to report de-
scriptively on the uptake of biosimilar infliximab, we ob-
tained data from the CMS Part B National Summary Data
File [13]. These data describe the use of various healthcare
services and associated Medicare-approved amounts for
medical procedures (including infusion therapies) by
CMS’ Medicare program, through December 31, 2017.
Results
Through the end of 2016, among 386,997 administra-
tions of infliximab, fewer than 1% were for the biosimilar
infliximab-dyyb (Q5102), and the median price per 100
mg infliximab vial was $829. After applying the inclusion
and exclusion criteria (Additional file 2: Figure S1), 5174
patients initiated infliximab, and 2843 patients initiated
golimumab IV. The characteristics both of patients who
received treatment and of the clinicians who prescribed
the medications were relatively similar for infliximab
and golimumab (Table 1). However, prescribers of goli-
mumab IV were older and had been in practice longer
than prescribers of infliximab, and were more likely to
own their own infusion practice. Golimumab-treated pa-
tients were slightly older (70.0 versus 68.6 years), less
likely to be dual eligible, and more likely to receive
monotherapy (i.e., without methotrexate or other con-
ventional synthetic DMARDs).
Overall non-persistence with golimumab IV was worse
than for infliximab (Fig. 1a, p < 0.0001). However, when
a composite outcome of non-persistence or dose
escalation was considered, the time to the composite
outcome was shorter for the infliximab users (Fig. 1b,
p < 0.0001). Approximately three quarters of infliximab
users discontinued or dose escalated by 18months.
Fewer than 5% of golimumab IV patients dose esca-
lated, whereas approximately half of infliximab patients
dose escalated, through 18months. Comparing patients
who dose escalated infliximab or golimumab IV to those
who did not (Additional file 1: Table S1) revealed few
characteristics that differentiated infliximab users who
dose escalated from those who did not. There were
several differences between golimumab IV users who
underwent dose escalation and those who did not and
their treating clinicians. The clinicians who dose esca-
lated patients were somewhat older, had been in practice
longer, and were more likely to be in office-based prac-
tice. Patients who had a higher prevalence of certain
comorbidities (e.g., chronic pulmonary disease, periph-
eral vascular disease) were more likely to undergo dose
escalation.
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As shown in Table 2, the mean [SD] costs paid by
Medicare over the first 18 months of treatment were sig-
nificantly greater for golimumab IV ($28,146 [16,030])
than for infliximab ($21,216 [15,819]), a 33% difference.
When the analysis was restricted to the minority of pa-
tients who persisted on therapy through 18months with
no gap in treatment > 10 weeks, least square mean costs
were 27% higher for golimumab IV ($43,940) than for
infliximab ($34,671).
The sensitivity analysis, which required only a single
dose increase or dosing frequency shortening after the
baseline dose and classified all patients in mutually ex-
clusive categories based on their maximal dose and dos-
ing frequency for any infusion through 18 months, is
shown in Fig. 2. Only about 40% of infliximab-treated
patients were observed to continue on 3mg/kg at an
every 8-week dosing interval. One third (33.9%) of pa-
tients increased their dose to 5mg/kg, and 8-9% in-
creased their dose to ≥ 8 mg/kg or 10mg/kg.
After multivariable adjustment, physician ownership of
the infusion center was associated with a 25% greater
likelihood of infliximab dose escalation (Table 3). Older
patient age, female sex, presence of chronic pulmonary
disease, being disabled, and being a dual eligible benefi-
ciary were associated with a lower likelihood of dose
escalation.
In the modeling scenario used to evaluate the dose
and frequency of infliximab that would be required to
offset the higher costs of golimumab IV, all dosing fre-
quencies of infliximab at doses of either 3 mg/kg or 5
mg/kg (with no discounting) yielded lower annual costs
when compared to golimumab IV. For infliximab doses
≥ 8 mg/kg, results are shown in Fig. 3 (with the under-
lying data for all key dose and frequency combinations
available in Additional file 1: Table S1). Positive
Table 1 Baseline characteristics of patients initiating golimumab







Female sex 679 (23.9%) 1368 (26.4%) 0.06
Age in years, mean (STD) 52.74 (9.43) 51.40 (9.29) 0.14
Years in practice 20.75 (10.86) 18.68 (10.81) 0.19
Ownership of infusion center 2528 (88.9%) 4162 (80.4%) 0.24
Office-based practice** 2230 (78.4%) 3906 (75.5%) 0.07
Type of employment
Federal government 108 (3.8%) 185 (3.6%) 0.01
Group practice 1298 (45.7%) 2237 (43.2%) 0.05
Local government 180 (6.3%) 409 (7.9%) 0.06
Medical school 79 (2.8%) 110 (2.1%) 0.04
Other 567 (19.9%) 1187 (22.9%) 0.07
Solo practice 611 (21.5%) 1046 (20.2%) 0.03
Patient-specific factors
Demographics
Age in years, mean (STD) 70.01 (8.90) 68.66 (9.47) 0.15
Female 2287 (80.4%) 3988 (77.1%) 0.08
White 2349 (82.6%) 4233 (81.8%) 0.02
Dual eligible for Medicare
and Medicaid
348 (12.2%) 886 (17.1%) 0.14
Disability according to
Medicare as original reason
for Medicare eligibility
1004 (35.3%) 1676 (32.4%) 0.06
Comorbidity diagnoses, %
Myocardial infarction 137 (4.8%) 226 (4.4%) 0.02
Coronary heart disease 554 (19.5%) 977 (18.9%) 0.02
Peripheral vascular disease 217 (7.6%) 389 (7.5%) 0.00
Chronic pulmonary disease 771 (27.1%) 1359 (26.3%) 0.02
Peptic ulcer disease 52 (1.8%) 86 (1.7%) 0.01
Diabetes 658 (23.1%) 1168 (22.6%) 0.01
Renal disease 287 (10.1%) 462 (8.9%) 0.04
Malignancy 195 (6.9%) 331 (6.4%) 0.02
Fibromyalgia 591 (20.8%) 978 (18.9%) 0.05
RA and other medications, %
Methotrexate 1642 (57.8%) 3595 (69.5%) 0.25
Other conventional
DMARDS
1085 (38.2%) 2386 (46.1%) 0.16
Oral glucocorticoids 2039 (71.7%) 3914 (75.6%) 0.09
NSAIDs 1299 (45.7%) 2453 (47.4%) 0.03
Opioid 2030 (71.4%) 3585 (69.3%) 0.05
Statin 1315 (46.3%) 2219 (42.9%) 0.07
Other lipid lowering drug 257 (9.0%) 418 (8.1%) 0.03
Anti-hypertensive drug 2202 (77.5%) 3822 (73.9%) 0.08
Anti-depressant drug use 1283 (45.1%) 2181 (42.2%) 0.06
Table 1 Baseline characteristics of patients initiating golimumab








Number of physician visits,
Mean (STD)
17.89 (9.35) 16.96 (9.17) 0.10
Any hospitalization 604 (21.2%) 1027 (19.8%) 0.03
Colon cancer screening 442 (15.5%) 931 (18.0%) 0.07
Breast cancer screening 1197 (42.1%) 2097 (40.5%) 0.03
SMD standardized mean difference. A SMD > 0.10 (italicized) is indicative of a
potentially important difference
Data shown as mean (standard deviation) or n (%)
*Two consecutive infusions with a dose increase, or frequency increase, were
required to satisfy this definition
**Rather than hospital-based practice, research, or other/missing designations
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numbers (above the zero line on the y axis) reflect
higher costs for infliximab, and negative numbers reflect
lower costs for infliximab, referent to golimumab IV,
and are shown to four body weights. Infliximab at 8 mg/
kg became less costly than golimumab IV once discounts
of greater than 25% were available. At 10 mg/kg dosed
every 6 weeks, however, the cost of infliximab was lower
than that of golimumab IV only if discounts greater than
of approximately 30% or more were applied (depending
on body weight); at 10 mg/kg dosed every 4 weeks,
discounts of 50% or more would be needed in order to
yield a lower cost for infliximab compared to that of
golimumab IV. Finally, based on aggregate part B data
available from CMS for January 2017 through December
2017, the proportion of Medicare-approved charges for
biosimilar infliximab as a fraction of all infliximab Medi-
care allowed charges had grown to 5.1% (Q5101, 2.6%;
Q5102, 2.5%).
Discussion
In this analysis of real-world data from the US Medicare
program, we found that infliximab dose escalation was
common, occurring in approximately one half of pa-
tients during the first 18 months of treatment. However,
given the appreciately higher drug-related cost of goli-
mumab IV relative to infliximab, treatment with inflixi-
mab became more expensive only if patients escalated
the infliximab dose to at least 8 mg/kg. Even in that cir-
cumstance, a 20% or greater discount to the amount re-
imbursed for infliximab largely offset the increased
expense of infliximab incurred by escalating the dose up
to 8 mg/kg every 6 weeks. Given the 21% lower average
sales price (ASP) of biosimilar infliximab-dyyb, as com-
pared to the ASP of bio-originator infliximab, in Q3
2019 (Additional file 3: Figure S2) [10], even infliximab
dose at 8 mg/kg q 6 weeks should be approximately neu-
tral or cost saving compared to golimumab IV. However,
at 10 mg/kg dosed every 4 weeks, infliximab would have
to be discounted by 50–60% to achieve parity with the
cost of golimumab IV, a circumstance that is perhaps
unlikely to occur in the US in the near future.
We found that dose escalation of infliximab is com-
mon in this cohort of RA patients. Indeed, only about
40% of patients remained on their starting dose, which is
typically 3 mg/kg q 8 weeks for RA. While the oper-
ational definitions of dose escalation may vary from
study to study and may differ somewhat according to
the data source, approximately 30–60% of RA patients
in the US typically dose escalate [14–17]. While one
might contend that infliximab dose escalation can
achieve incremental clinical benefit, most published
studies that have examined clinical outcomes have not
found improved control of disease activity with inflixi-
mab compared to other TNFi therapies, even with its
potential for dose and frequency escalation [18–21].
Perhaps of importance, we found that patients treated
by physicians who owned the infusion practice were
more likely to undergo dose escalation, similar to prior
observations [22]. We also observed that dose escalation
was associated with several patient characteristics. Youn-
ger individuals, men, and those who did not have
chronic pulmonary disease were more likely to dose es-
calate. Those who were dual eligible and disabled were
less likely to dose escalate, which may reflect the fact
Fig. 1 a KM curves for persistence with infliximab and intravenous
golimumab. Note: non-persistence defined as a gap > 10 weeks in
therapy. b KM curve for the composite outcome of persistence or
dose escalation of infliximab and intravenous golimumab. Note:
non-persistence defined as a gap > 10 weeks in therapy
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that these patients who also have Medicaid coverage
(i.e., because they are dual eligible) have a broader range
of treatment choices available to them, including self-
injected and oral targeted therapies (e.g., tofacitinib).
Previously published studies have shown that despite
infliximab dose escalation, patients typically achieve clin-
ical outcomes comparable to those with other biologics
used to treat RA [23, 24], yet dose escalation appears to
confer a greater risk of serious infections [25]. Dose es-
calation also results in increased costs, both financial
direct costs, as described in this and other studies [16,
18, 26], and indirect costs including the time burden to
patients of more frequent and longer duration of infu-
sions. Thus, despite the availability and potential cost
savings of biosimilars, infliximab dose escalation beyond
5mg/kg is probably not a prudent course of treatment
for most RA patients compared to switching to alterna-
tive treatment options.
The strengths of our study include a relatively large
sample size of patients receiving care in the US. The
generalizability of the US Medicare population to older
individuals is excellent, in that Medicare covers approxi-
mately 94% of the US population age ≥ 65 years. More-
over, we were able to examine physician ownership of
Table 2 Dose escalation and IPTW-adjusted Medicare-approved amount for the biologic medication through week 78, in both the
as-observed and persistent cohorts
Infliximab (N = 5174) Golimumab (N = 2843) p value
Overall cohort
Dose escalation*, % 49.46 4.89 < 0.0001
Dose increase, % 39.49 3.17 < 0.0001
Frequency increase, % 29.15 1.79 < 0.0001
Discontinuation, % 73.33 79.85 < 0.0001
Biologic Medicare-approved amounts, day 0–546, $
All biologics**
LS mean (95% CI) 26,934 (26,441–27,435) 35,512 (34,849–36,187) < 0.0001
Index biologic
LS mean (95% CI) 21,216 (20,737–21,706) 28,146 (27,497–28,810) < 0.0001
Biologic Medicare-approved amounts, day 183–546, $
All biologics**
LS mean (95% CI) 16,401 (15,699–17,135) 20,512 (19,615–21,450) < 0.0001
Index biologic
LS mean (95% CI) 11,488 (10,813–12,205) 14,055 (13,213–14,951) < 0.0001
Persistent cohort (no switch or gap > 10 weeks) N = 1380 N = 573
Dose escalation*, % 71.96 7.85 < 0.0001
Dose increase, % 58.55 5.24 < 0.0001
Frequency increase, % 45.00 2.97 < 0.0001
Biologic Medicare-approved amounts, day 0–546, $
Index biologic
LS mean (95% CI) 34,671 (33,891–35,470) 43,940 (42,849–45,058) < 0.0001
Biologic Medicare-approved amounts, day 183–546, $
Index biologic
LS mean (95% CI) 22,877 (22,301–23,467) 27,454 (26,692–28,238) < 0.0001
LS inverse probability treatment (IPTW)-weighted least square mean
IPTW weighting controlled for patient age, sex, race, number of physician visits, number of prior biologic DMARDS, methotrexate use, statin use, reason for eligible
for Medicare, and 55 of the CCS categories (Additional file 1: Table S2) which were significant in univariate analyses in their association with cost from
day 183–546
*Dose and frequency increases are not mutually exclusive. Note that two consecutive infusions were required to meet definition for dose and
frequency escalation
**Includes cost of both the index therapy (infliximab or golimumab) and any subsequent biologic switch through day 546. Costs from day 183–546 were shown
to be able to describe costs following the loading period for each drug
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the infusion center that might influence motivation to
continue to keep people on an intravenous therapy and
to escalate the dose of the infused medication. Neverthe-
less, our results must be interpreted in light of our study
design. We lacked information on the clinical reasons
for treatment discontinuation (e.g., lack of clinical re-
sponse, safety/tolerability) and dose escalation. We did
not study safety- or tolerability-related factors, although
infliximab has been commonly associated with mild in-
fusion reactions and infrequently with severe infusion
reactions [27].
Our data extended through the end of 2016. Biosimilar
infliximab-dyyb was first marketed in the US on November
28, 2016 [28], and we observed minimal use of biosimilar
infliximab through the end of that year. However, it likely
has increased appreciably in a more contemporary time in
2018 [29]. Moreover, as of April 1, 2018, the Medicare pro-
gram changed the coding and reimbursement for biosimilar
infliximab, replacing the HCPCS code Q5102 under which
all biosimilar infliximab products were grouped with indi-
vidual HCPCS codes Q5103 for biosimilar infliximab-dyyb
and Q5104 for biosimilar infliximab-abda, which allowed
each product to have its own ASP [30]. Since a biosimilar is
reimbursed at its own ASP plus 6% of the ASP of its refer-
ence product, the introduction of unique HCPCS codes for
individual biosimilars creates price competition among bio-
similars and has resulted in further reductions in the cost
of infliximab, both bio-originator and biosimilars (Add-
itional file 3: Figure S2) [30]. However, unlike the discounts
of up to 70% that have been achieved for biosimilar inflixi-
mab in the Norwegian tender system [6], price reductions
sufficient to offset the higher costs of infliximab dose escal-
ation to 10mg/kg infused every 4 or 6 weeks may not be
attainable in the US.
Conclusion
The costs associated with dose escalating infliximab
to 10 mg/kg every 4 or 6 weeks are substantial and
likely offset even appreciable dose savings associated
with biosimilars. Under those circumstances, use of
an alternative medication (e.g., golimumab IV) is
likely to be less expensive and, on average, has been
shown to result in similar clinical outcomes. For all
other lower infliximab doses and frequencies, how-
ever, the costs associated with dose escalation likely
would be offset by the savings associated with use of
Fig. 2 Maximum dose and frequency of infliximab administered through 18months* (n = 4502). *Restricted to patients with a consistent dose for
all 3 infusions, throughout the induction period (week 0, 2, 6), at starting doses of 200, 300, or 400 mg, representing 87% of all 5174 patient in the
infliximab cohort. All patients were assumed to be starting at a dose of 3 mg/kg, every 8 weeks. In this analysis, only a single dose and frequency
increase was required, unlike in the main analysis where two consecutive infusions were required to meet the dose escalation definition.
**Infusion interval for q6w infusion ranges from 36 to 48 days, inclusive (42 ± 6 days). ***Infusion interval for q4w infusion ranges from 22 to 34
days, inclusive (28 ± 6 days)
Table 3 Baseline factors associated with infliximab dose
escalation (n = 5174 initiators)
Factor Adjusted* odds ratio
(95% CI)
Physician ownership of infusion practice 1.25 (1.09–1.44)
Patient age (5 year increments) 0.93 (0.89–0.96)
Male sex 1.20 (1.04–1.40)
Chronic pulmonary disease 0.84 (0.74–0.95)
Disability 0.84 (0.72–0.98)
Dual eligibility 0.79 (0.66–0.94)
*Also adjusted for race, use of other conventional synthetic DMARDs, use of
oral glucocorticoid, NSAIDs, opioids, statins, anti-hypertensive medications,
lipid lowering medications, anti-depressants, and breast cancer screening,
none of which were significant
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biosimilar infliximab. Finally, although cost is an im-
portant consideration in selecting among biologics,
other clinical factors (e.g., shorter infusion time, lower
incidence of hypersensitivity infusion reactions, and
incidence of serious infections) should be considered
when selecting a specific biologic agent.
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